v3.26.1
Revenue - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2025
May 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]                
Revenue $ 0 $ 224,000 $ 422,000 $ 366,000        
Upfront cash payment received $ 55,218,000   55,218,000   $ 52,096,000 $ 55,622,000    
Collaboration Agreement with AstraZeneca                
Disaggregation of Revenue [Line Items]                
Revenue     400,000 400,000        
Upfront cash payment received             $ 40,000,000 $ 20,000,000
Milestone payments received     $ 0 $ 0 $ 10,000,000